tirzepatide also known as Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review Benefits of Mounjaro for Medical

49 Treatment with liraglutide 0.9 mg daily and 1.2 mg daily after 96 weeks and six months, respectively, both demonstrated reductions in hepatic steatosis, and the 0.9 mg treatment group underwent histological assessment revealing improvement in hepatitis

These patients successfully lost more than 6% Trusted Source PubMed Central Go to source of their body weight, but the treatment had no effect on IBD activity

Since GLP-1 impacts hunger perception and taste preferences, it can naturally drive dietary changes over time, shifting eating habits towards more nutrient-dense choices without conscious restriction

Adjustments may be made based on how the patient tolerates the medication, their appetite, or doctor recommendations

You can review the CDC data in its state obesity prevalence report